AMRI Wins Four Life Science Leader Awards

Mar 14, 2016, 08:00 ET from AMRI

ALBANY, N.Y., March 14, 2016 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has been recognized as a Life Science Leader CMO Leadership Award recipient in the categories of Expertise (overall, small pharma), Capabilities (small pharma) and Compatibility (small pharma). In 2013, AMRI was awarded a CMO Leadership Award in the Quality category.

This year's awards will be presented at the CMO Leadership Awards Ceremony and Reception at the W Hotel on Wednesday, March 16, 2016 in New York City. Each year, recipients are evaluated by executives and managers of the CMO's sponsors in five categories, which include Capabilities, Compatibility, Expertise, Quality, and Reliability.

"We are honored to be acknowledged once again as a CMO Leadership Award Winner," said William S. Marth, President and CEO, AMRI. "This recognition underscores how our customers and peers feel about working with us and the confidence they have in our expertise. This award comes at an extraordinary time for our company. It is a pivotal time for AMRI as we continue to dramatically expand our services building a strong platform for our business and a stronger pharmaceutical development and manufacturing company for tomorrow's pharmaceutical market. We are pleased to receive the award and would like to congratulate the rest of the CMO award winners."

To establish this year's winners, Life Science Leader worked with Industry Standard Research (ISR). ISR's Contract Manufacturing Quality Benchmarking research is conducted annually via an online survey. For the 2016 CMO Awards data, 83 contract manufacturers were evaluated on 26 different performance metrics. Research participants were recruited from biopharmaceutical companies of all sizes and were screened for decision-making influence and authority when it comes to working with contract manufacturing suppliers. Respondents only evaluated companies with which they have worked on an outsourced project within the past 18 months. This level of qualification ensured that quality ratings came from actual involvement with a business and that companies identified as leaders were backed by experiential data.

AMRI, which is a fast-growing contract research, development and manufacturing company serving the brand and generic pharmaceutical markets, is growing a portfolio of complex API. The company enters 2016 with an API manufacturing pipeline that includes 50 compounds in Phase I and II and 14 in Phase III, with 27 DMFs and 148 commercial products. On the drug product side, there are 69 aseptic fill finish products in Phase I and II, 21 in Phase III, with 23 under regulatory review and 17 in commercial production.

About AMRI
Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), and Drug Product Manufacturing (DPM). Our DDS segment provides comprehensive services from hit identification to IND, including expertise with diverse chemistry, library design and synthesis, in vitro biology and pharmacology, drug metabolism and pharmacokinetics, as well as natural products. API supports the chemical development and cGMP manufacture of complex API, including potent and cytotoxic compounds, controlled substances, steroids, peptides, hormones, and sterile API. DPM supports development through commercial scale production of complex liquid-filled and lyophilized parenterals, sterile suspensions and ophthalmic formulations. For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal).

SOURCE AMRI



RELATED LINKS

http://www.amriglobal.com